Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Systagenix Wound Management Ltd.

Division of Acelity LP Inc.
www.systagenix.com

Latest From Apotex Inc.

Biosimilars Payments In Medicare: CMS Signals Willingness To Change

Policy of paying for all biosimilars referencing the same drug at one blended rate is under review, to the relief of product developers and other stakeholders.

Biosimilars Medicare

US Biosimilars: 40% First-Cycle Approval Rate Leaves Room For Improvement

Four of first 10 publicly disclosed applications were approved on first review cycle, and FDA has issued at least seven complete response letters. Increasing first-cycle approvals is a primary goal of the BsUFA II agreement.

Biosimilars Drug Review

The End Of Generics Mergers? Too Much Effort, No Reward!

There has been $150bn worth of merger and acquisition activity since 2012 in the generic medicines arena, yet the sector is more fragmented than it was five years ago. CEOs and analysts from the generics sector believe that investor-propelled moves towards greater consolidation have been thwarted by the market agility of smaller companies. And now the cost of M&A has burdened major generics firms with debt.

Generic Drugs M & A

AstraZeneca Defeats Canada's Patent 'Promise Doctrine' Through Court, Not NAFTA

Supreme Court of Canada says promise doctrine is not correct approach to determine if a patent has sufficient utility; doctrine has been used to invalidate patents on 22 medicines.

Intellectual Property Legal Issues
See All

Company Information

  • Industry
  • Biotechnology
  • Medical Devices
    • Biomaterials
  • Therapeutic Areas
  • Wound Healing & Tissue Repair
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • Acelity LP Inc.
  • Senior Management
  • Peter Huntley, SVP, Head
  • Contact Info
  • Systagenix Wound Management Ltd.
    Phone: 1293 842000
    2 City Pl., Beehive Ring Rd.
    Gatwick, RH6 0PA
    UK
Advertisement
Advertisement
UsernamePublicRestriction

Register